{"title": "2023 Biological License Application Supplement Noteworthy Approvals", "author": "Center; Research", "url": "https://www.fda.gov/vaccines-blood-biologics/development-approval-process-cber/2023-biological-license-application-supplement-noteworthy-approvals", "hostname": "fda.gov", "description": "Listing of the 2023 Biological License Application Supplement Noteworthy Approvals", "sitename": "FDA", "date": "2023-08-18", "cleaned_text": "| |[ERVEBO](/vaccines-blood-biologics/ervebo) Ebola Zaire Vaccine, Live |To extend the indication for use to include individuals 12 months of age and older. ||125690/55 ||Merck Sharp & Dohme LLC | 351 N. Sumneytown Pike P.O. Box 1000 North Wales, PA 19454 Lic. # 0002 |07/27/2023 | | |[DENGVAXIA](/vaccines-blood-biologics/dengvaxia) Dengue Tetravalent Vaccine, Live |To include safety and efficacy data that support the use of DENGVAXIA in individuals 6 through 16 years of age with laboratory-confirmed previous dengue infection and living in endemic areas. ||125682/40 ||Sanofi Pasteur Inc. | Discovery Drive Swiftwater, PA # 1725 |06/30/2023 | | |[BOOSTRIX](/vaccines-blood-biologics/vaccines/boostrix) Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed |To include data on safety and the immune responses to BOOSTRIX when administered concomitantly with Zoster Vaccine Recombinant, Adjuvanted # 1617 |06/14/2023 | | Meningococcal (Groups A, C, Y, W) Conjugate Vaccine |To include safety and effectiveness data from clinical studies MET59 and MEQ66 in support of booster vaccination of individuals 13 years of age and older who are at continued risk for meningococcal disease if at least 3 years have elapsed since a prior dose of meningococcal (groups A, C, W, Y) conjugate vaccine, and vaccination following a prior dose of meningococcal polysaccharide vaccine if at least 3 years have elapsed since the prior dose of meningococcal polysaccharide vaccine. ||125701/128 ||Sanofi Pasteur Inc. from study V114-022 in the \"Use in Specific Populations\" section of the package insert, for pediatric and adult recipients of allogenic hematopoietic stem-cell transplant (allo-HSCT). ||125741/123 ||Merck 351 N. Sumneytown Pike P.O. Box 1000 Suite UG2D-68 North Wales, PA 19454-2505 Lic. # 0002 |05/25/2023 | | |[SHINGRIX](/vaccines-blood-biologics/vaccines/shingrix) Zoster Vaccine Recombinant, Adjuvanted |To include data on safety and the immune responses to SHINGRIX when administered concomitantly with Pneumococcal Vaccine Polyvalent 13-valent or Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed (BOOSTRIX), or following Zoster Vaccine Live (ZOSTAVAX). ||125614/700 ||GlaxoSmithKline | 1400 Human Papillomavirus 9-valent Vaccine, Recombinant |To include clinical data from the long-term follow-up study V503-002-20 in support of modifications to the package insert. ||125508/1434 ||Merck Sharp & Dohme LLC | 126 East Lincoln Ave. P.O. Box 2000 Rahway, NJ 07065 Lic. # 0002 |04/28/2023 | | |[COAGADEX](/vaccines-blood-biologics/approved-blood-products/coagadex) Coagulation Factor X, (human) |To expand the indication for perioperative management of bleeding to include patients with severe hereditary Factor X deficiency based on submission of the final study report for Study TEN06, intended to fulfill the Postmarketing Commitment #1. ||125506/164 ||Bio Products Laboratory Limited | 302 East Pettigrew Suite C-190 Durham, NC 27701 Lic. # 1811 |04/14/2023 | | |[HYQVIA](/vaccines-blood-biologics/approved-blood-products/hyqvia) Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase |To extend the indication of Primary Immunodeficiency Diseases to pediatric patients from 2 years of age 16 years of age. ||125402/818 ||Baxalta US Inc. | 650 East Kendall Street Cambridge, MA 02142 Lic. # 1898 |04/07/2023 | | Vaccine Live |To include safety and immunogenicity data that support the intramuscular route as an additional route of administration for M-M-R II, and associated product labeling changes. ||101069/5846 ||Merck Sharp & Dohme Corp. | 351 N. Sumneytown Pike P.O. Box 1000 UG2D-68 North Wales, PA 19454 Lic. # 0002 |02/27/2023 | | |[VARIVAX](/vaccines-blood-biologics/vaccines/varivax-refrigerated-and-frozen-formulations) Varicella Virus Vaccine Live |To include safety and immunogenicity data that support the intramuscular route as an additional route of administration for VARIVAX, and associated product labeling changes. ||103552/6277 ||Merck Sharp & Dohme Corp. | 351 N. Sumneytown Pike P.O. Box 1000 UG2D-68 North Wales, PA Vaccine Live |To include safety and immunogenicity data that support the intramuscular route as an additional route of administration for ProQuad, and associated product labeling changes. ||125108/1128 ||Merck Sharp & Dohme Corp. | 351 N. Sumneytown Pike P.O. Box 1000 UG2D-68 North Wales, PA # |02/27/2023 | | |[DENGVAXIA](/vaccines-blood-biologics/dengvaxia) Dengue Tetravalent Vaccine, Live |To include data on the immune response to Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine administered concomitantly DENGVAXIA ||Sanofi Pasteur Discovery Drive Lic. # 1725 |01/25/2023 | Dermatophagoides pteronyssinus) Allergen Extract |To include use in adolescents 12 through 17 years of age ||125592/157 ||ALK-Abello A/S | 135 Route 135 202/206 Bedminster, NJ Lic. # 1292 |01/20/2023 | | |[ADACEL](/vaccines-blood-biologics/vaccines/adacel) Tetanus Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed |To include immunization during the third trimester of pregnancy to prevent pertussis in infants younger than 2 months of age. ||125111/904 ||Sanofi Pasteur Limited | 1755 Steele Avenue Toronto, Ontario Canada M2R 3T4 Lic. # 1726 |01/09/2023 | "}